Communication
ChemComm
Program (DoD W81XWH0920176). Authors thank Brett Meers
for technical assistance, and facility support of Truman VA
Biomolecular Imaging Center, MO 65201, USA.
Conflicts of interest
There are no conflicts to declare.
Notes and references
1 V. M. Runge, Invest. Radiol., 2017, 52, 317–323.
´
´
2 J. Wahsner, E. M. Gale, A. Rodrıguez-Rodrıguez and P. Caravan,
Chem. Rev., 2019, 119, 957–1057.
Fig. 2 (A) Comparison of per Gd r1 relaxivity for CCA-I and Omniscan in
PBS, 2% TWEEN-80 and bovine calf serum at 7 T and 25 1C. (B) T1-Weighted
MRI of CCA-I at various concentrations in PBS compared with Omniscan.
(C) In vivo T1-weighted MRI of SCID mice bearing PC-3 tumors before, 2 min,
30 min and 1 h after intravenous injection of CCA-I (top) and Omniscan
(bottom) at a Gd dose of 0.04 mmol kgꢀ1 and 7 T.
3 S. Aime, D. D. Castelli, S. G. Crich, E. Gianolio and E. Terreno,
Acc. Chem. Res., 2009, 42, 822–831.
4 M. A. Pysz, S. S. Gambhir and J. K. Willmann, Clin. Radiol., 2010, 65,
500–516.
5 T. J. Clough, L. Jiang, K.-L. Wong and N. J. Long, Nat. Commun.,
2019, 10, 1420.
6 H.-K. Kim, G. H. Lee and Y. Chang, Future Med. Chem., 2018, 10,
639–661.
7 S. M. Vithanarachchi and M. J. Allen, Curr. Mol. Imaging, 2012, 1,
12–25.
8 J. L. Major and T. J. Meade, Acc. Chem. Res., 2009, 42, 893–903.
9 I. Craciun, G. Gunkel-Grabole, A. Belluati, C. G. Palivan and
W. Meier, Nanomedicine, 2017, 12, 811–817.
10 J. R. Lloyd, P. S. Jayasekara and K. A. Jacobson, Anal. Methods, 2016,
8, 263–269.
11 S. P. Fisher, A. W. Tomich, S. O. Lovera, J. F. Kleinsasser, J. Guo,
M. J. Asay, H. M. Nelson and V. Lavallo, Chem. Rev., 2019, 119,
8262–8290.
Finally, the in vivo potential of CCA-I was investigated in
severely compromised immunodeficient (SCID) mice bearing
human PC-3 prostate cancer xenografts. Six mice per group
were given intravenous injections of CCA-I or Omniscan at a Gd
dose of 0.04 mmol kgꢀ1 body weight. Sequential T1-weighted
MRI was performed pre and post-injection. The CCA-I group
exhibited strong and prolonged tissue enhancement in tumor
and kidneys compared to the Omniscan group (Fig. 2C). Tumor 12 S. P. Fisher, A. W. Tomich, J. Guo and V. Lavallo, Chem. Commun.,
2019, 55, 1684–1701.
13 J. C. Axtell, L. M. A. Saleh, E. A. Qian, A. I. Wixtrom and A. M.
signal enhancement by CCA-I persisted up to 4 h followed by
complete renal clearance in 24 h (Fig. S7, ESI†). Quantitative
Spokoyny, Inorg. Chem., 2018, 57, 2333–2350.
˜
´
analysis showed that the contrast enhancement ratio (CER) by 14 R. Nu´nez, M. Tarres, A. Ferrer-Ugalde, F. F. de Biani and F. Teixidor,
CCA-I was significantly higher in tumors at 30 min and 1 h and
in kidneys at 1 h than that by Omniscan (Fig. S8, ESI†).
Chem. Rev., 2016, 116, 14307–14378.
15 M. F. Hawthorne and A. Pushechnikov, Pure Appl. Chem., 2012,
84, 2279.
In summary, we hereby report a monodisperse, nano-sized, 16 S. J. Sarma, A. A. Khan, L. N. Goswami, S. S. Jalisatgi and M. F.
Hawthorne, Chem. – Eur. J., 2016, 22, 12715–12723.
17 S. Aime, L. Calabi, C. Cavallotti, E. Gianolio, G. B. Giovenzana, P. Losi,
multimeric closomer MRI contrast agent CCA-I, based on icosa-
hedral closo-borane scaffold. The unique configuration of twelve
A. Maiocchi, G. Palmisano and M. Sisti, Inorg. Chem., 2004, 43, 7588–7590.
´
modified Gd-AAZTA chelates configured tightly in a sterically 18 Z. Baranyai, F. Uggeri, G. B. Giovenzana, A. Benyei, E. Bru¨cher and
S. Aime, Chem. – Eur. J., 2009, 15, 1696–1705.
19 M. C. Alpoim, A. M. Urbano, C. F. G. C. Geraldes and J. A. Peters,
confined space exhibits high relaxivity. New versions of the AAZTA
chelate, with functionalizable amine, hydroxyl and alkyne end
J. Chem. Soc., Dalton Trans., 1992, 463–467.
groups are also reported that can be used as precursors for 20 L. N. Goswami, S. Chakravarty, M. W. Lee, S. S. Jalisatgi and
M. F. Hawthorne, Angew. Chem., Int. Ed., 2011, 50, 4689–4691.
21 L. N. Goswami, L. Ma, S. Chakravarty, Q. Cai, S. S. Jalisatgi and
attachment to various biological targets.
This research was funded by National Cancer Institute
M. F. Hawthorne, Inorg. Chem., 2013, 52, 1694–1700.
´
´
(R21-CA114090) and University of Missouri, MO 65212, USA. 22 E. Bru¨cher, G. Tircso, Z. Baranyai, Z. Kovacs and A. D. Sherry, The
E. M. S. was funded by National Institute of Diabetes and
Digestive and Kidney Diseases (R01-DK-107697). L. M. was
Chemistry of Contrast Agents in Medical Magnetic Resonance Imaging,
John Wiley & Sons, Ltd, Chichester, UK, 2013, pp. 157–208.
23 Bracco S.p.A., Eur. Pat., EP1964846 (A1), Universita di Trieste, Italy,
funded by Department of Defense Prostate Cancer Research
2008, p. 34; Chemical Indexing Equivalent to 149:326295.
This journal is ©The Royal Society of Chemistry 2019
Chem. Commun., 2019, 55, 12348--12351 | 12351